Mymetics Corp (MYMX)

[Work Harder]

KEYWORDS: Immuno-oncology, peptide cancer vaccines, B-cell epitopes, PD-1, PD-L1, nivolumab; CT26/HER-2 model, CT26 carcinoma, HER-2

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553530/

96. Wiedermann U, Wiltschke C, Jasinska J, Kundi M, Zurbriggen R,
Garner-Spitzer E, et al. A virosomal formulated Her-2/neu multi-peptide
vaccine induces Her-2/neu-specific immune responses in patients with
metastatic breast cancer: a phase I study. Breast Cancer Res Treat. 2010; 119:
673-83

99. Bekaii-Saab T, Overholser J, Yang Y, Penichet M, Kaumaya P. Development of
a novel PD-1 vaccine and in combination with two Chimeric HER-2 peptide
vaccine provides synergistic inhibition of tumor growth in a syngeneic Balb/c
model challenged with CT26/HER-2 carcinoma cell line. AACR; 2019

https://www.thno.org/v09p7807.pdf

Virosomes themselves as anti-cancer reagents
Surprisingly, recent studies have shown that virosomes may have anti-tumor activities just by themselves. Kurooka et al. (81) have demonstrated that direct injection of the
HVJ envelope into murine colon carcinoma (CT26) tumors growing in syngeneic BALB/c
mice can eradicate 60 to 80 % of the tumors by both production of tumor-specifi c cytotoxic T cells and blocking of regulatory T cell activity. HVJ-E injection has also been shown
to inhibit Renca tumor growth by enhancing local CXCL10 expression and systemic NK
cell activation (82).

Check out the other references

https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwjM96Sr9drwAhVMJKwKHQ0uD5wQFjAFegQIChAD&url=https%3A%2F%2Fcyberleninka.org%2Farticle%2Fn%2F1187906.pdf&usg=AOvVaw2azjXbKLz4JMXfoIYz0wdb

Description
CT26.WT (ATCC® CRL-2638™) is a murine colorectal carcinoma cell line from a BALB/c mouse. It is a clone of the N-nitroso-N-methylrethane-induced undifferentiated CT26 colon carcinoma cell line. The cells are adherent and have a fibroblast morphology. CT26.WT cells will form tumors and metastases post implantation into syngenic BALB/c mice or immunocompromised mice.

*The ATCC trademark and trade name and any and all ATCC catalog numbers are trademarks of the American Type Culture Collection.

Usage Information:
CT26.WT cells are suitable for in vitro and in vivo experimentation. Both syngenic BALB/c mice and immunocompromised mice can be used for in life studies, and will form tumors following implantation of the cells.

The following chart provides some examples of CT26.WT cells used for tumor formation and studies.

https://imanislife.com/collections/cell-lines/ct26-wt-cells/#:~:text=Description-,CT26.,and%20have%20a%20fibroblast%20morphology.

https://www.covance.com/industry-solutions/oncology/preclinical/tumor-spotlights/ct26-murine-colon-carcinoma.html